ERBB2 and breast carcinoma: Preclinical studies demonstrated SYD985’s efficacy in HER-2-overexpressing breast cancer cells, with similar HER-2 binding, HER2-mediated internalization and ADCC stimulation when compared with T-DM1 [95].